الإحصائيات الأساسية
| LEI | 549300RJTND7CT8R8853 |
| CIK | 891293 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CTI BioPharma Corp
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| July 6, 2023 |
15-12G As filed with the Securities and Exchange Commission on July 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) JAMES KRATKY BVF Partners L |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other Jurisdiction of Incorporation) (Commission File |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 4 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
FORM OF CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION EX-3.1 Exhibit 3.1 FORM OF CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION FIRST: The name of the corporation is CTI BioPharma Corp. (the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, County of New Castle, Wilmington, Delaware 19808. The name of the Corporation’s registered |
|
| June 26, 2023 |
SECOND AMENDED AND RESTATED BYLAWS CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I OFFICES Section 1.1 Registered Office. The initial registered office of the corporation in the State of Delaware shall be located at Corporation Service Company, 251 Little Falls Drive, County of New Castle, Wilmington, Delaware 19808. The name of the corporation’s initial registered agent at suc |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
Stockholm, Sweden, 26 June, 2023 EX-99.(a)(5)(v) Exhibit (a)(5)(v) Press release Stockholm, Sweden, 26 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDIC |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 POS AM As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
Stockholm, Sweden, 24 June, 2023 EX-99.(a)(5)(iv) Exhibit (a)(5)(iv) Press release Stockholm, Sweden, 24 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISD |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 13, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 3 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 12, 2023 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| June 12, 2023 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| June 9, 2023 |
SC TO-T/A 1 d491737dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 2 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH O |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 12648L6 |
|
| June 2, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 12648L6 |
|
| May 30, 2023 |
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders EX-99.1 Exhibit 99.1 CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders SEATTLE, Wash., May 30, 2023 - CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (th |
|
| May 30, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 25, 2023 |
Offer to Purchase Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES EX-99.(b)(2) Exhibit (b)(2) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred |
|
| May 25, 2023 |
Summary Advertisement Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| May 25, 2023 |
Form of Letter to Clients for use by Brokers, Dealers, etc Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
Form of Notice of Guaranteed Delivery Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
EX-99.A(5)(C) Exhibit (a)(5)(C) Centerview Partners LLC 31 West 52nd Street New York, NY 10019 May 10, 2023 The Board of Directors CTI Biopharma Corp. 3101 Western Avenue Suite 800 Seattle, WA 98121 The Board of Directors: You have requested our opinion as to the fairness, from a financial point of view, to the holders of the outstanding shares of common stock, par value $0.001 per share (the “Sha |
|
| May 25, 2023 |
Stockholm, Sweden, May 25, 2023 EX-99.(a)(5)(iii) Exhibit (a)(5)(iii) Press release Stockholm, Sweden, May 25, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURIS |
|
| May 25, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT Exhibit (d)(3) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT THIS MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (“Agreement”) is entered into as of March 3, 2023 (the “Effective Date”), by and between CTI BioPharma Corp. |
|
| May 25, 2023 |
Form of Letter of Transmittal Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 12648L601 (CUSIP Number o |
|
| May 25, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person— |
|
| May 25, 2023 |
Form of Letter to Brokers, Dealers, Commercial banks, Trust Companies and Other Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
SEK 8,000,000,000 EQUITY BRIDGE FACILITY EX-99.(b)(1) Exhibit (b)(1) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 SEK 8,000,000,000 EQUITY BRIDGE FACILITY We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred to as the “Banks” in such roles) a |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. |
|
| May 15, 2023 |
Amendment No. 2 to Severance Agreement by and between James Fong and CTI BioPharma Corp. Exhibit 10.2 CTI BIOPHARMA CORP. AMENDMENT NO. 2 TO SEVERANCE AGREEMENT This Amendment No. 2 to the Severance Agreement dated January 6, 2015 (this “Amendment”) is made by and between James Fong (“Employee”) and CTI BioPharma Corp., a Delaware corporation (the “Company” and together with Employee, the “Parties”) on the date set forth below. WHEREAS, the Parties previously entered into a Severance |
|
| May 15, 2023 |
Amendment No. 2 to Employment Agreement by and between Adam R. Craig and CTI BioPharma Corp. Exhibit 10.1 CTI BIOPHARMA CORP. AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement (this “Amendment”) is made by and between Adam R. Craig (“Executive”) and CTI BioPharma Corp., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the date set forth below. WHEREAS, the Parties previously entered into an Employment Agreement effecti |
|
| May 10, 2023 |
AMENDED AND RESTATED BYLAWS CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I REGISTERED OFFICE EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I REGISTERED OFFICE 1.1 Delaware Office. The Corporation shall have and maintain a registered office in the State of Delaware as required by law. The name and address of its registered agent in the State of Delaware is set forth in the Certificate of Incorporation of the Corporation (the Certificat |
|
| May 10, 2023 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) An Indirect Wholly Owned Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| May 10, 2023 |
EX-99.2 10th May, 2023 Acquisition of CTI Biopharma Expanding Sobi’s position in rare haematology Exhibit 99.2 This presentation contains forward-looking statements by Sobi that involve risks and uncertainties and reflect Sobi’s judgment as of the date of this presentation. These forward-looking statements generally are identified by words such as “believe,” “project,” “expect,” “anticipate,” “est |
|
| May 10, 2023 |
Highly confidential, for Internal use only. Do not distribute. EX-99.4 Exhibit 99.4 Highly confidential, for Internal use only. Do not distribute. The following frequently asked question list has been prepared to help explain the CTI-Sobi merger in more detail. If you have any further questions regarding the transaction, please contact your Supervisor, Derald Lo or John Volpone. 1. What did CTI announce? • We have entered into a definitive agreement to be acq |
|
| May 10, 2023 |
EX-99.2 Exhibit 99.2 Sobi to Acquire CTI BioPharma May 10, 2023 Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI’s Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ — CTI BioPharma (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, tod |
|
| May 10, 2023 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CTI BioPharma Corp. (Name of Subject Company) CTI BioPharma Corp. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 12648L601 (CUSIP |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 TO: All CTI Employees FROM: Adam Craig SUBJECT: Acquisition by SOBI—The Next Chapter of the CTI Story Dear CTI Colleagues I am very proud of the work we have done over the last few years to transform CTI into a successful and dynamic commercial organization. Throughout this time, we have all been aligned on one common mission – improving the lives of patients with cytopenic my |
|
| May 10, 2023 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: CTI BIOPHARMA CORP., a Delaware corporation; SWEDISH ORPHAN BIOVITRUM AB (PUBL), a Swedish public limited liability company; and CLEOPATRA ACQUISITION CORP., a Delaware corporation Dated as of May 10, 2023 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the C |
|
| May 10, 2023 |
Amended and Restated Bylaws of CTI BioPharma Corp. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I REGISTERED OFFICE 1.1 Delaware Office. The Corporation shall have and maintain a registered office in the State of Delaware as required by law. The name and address of its registered agent in the State of Delaware is set forth in the Certificate of Incorporation of the Corporation (the Certificate of In |
|
| May 10, 2023 |
EX-99.2 Exhibit 99.2 Subject: Sobi to Acquire CTI [Dear NAME / INSERT CUSTOMARY GREETING], Moments ago, we announced that we have entered into a definitive agreement to be acquired by Sobi for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion and an 89% premium to CTI’s closing share price on May 9, 2023. The press releas |
|
| May 10, 2023 |
[Dear NAME / INSERT CUSTOMARY GREETING], EX-99.3 Exhibit 99.3 [Dear NAME / INSERT CUSTOMARY GREETING], I wanted to reach out to share some exciting news about CTI. On Wednesday, May 10th, we announced that the Company has entered into a definitive agreement to be acquired by Sobi, a global healthcare leader in hematology, immunology and specialty care. By joining forces with Sobi, CTI will benefit from Sobi’s resources, scale and strong |
|
| May 10, 2023 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: CTI BIOPHARMA CORP., a Delaware corporation; SWEDISH ORPHAN BIOVITRUM AB (PUBL), a Swedish public limited liability company; and CLEOPATRA ACQUISITION CORP., a Delaware corporation Dated as of May 10, 2023 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the C |
|
| May 10, 2023 |
EX-99.2 Exhibit 99.2 Sobi to Acquire CTI BioPharma May 10, 2023 Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI’s Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ — CTI BioPharma (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, tod |
|
| May 10, 2023 |
Stockholm, Sweden, 10 Maj, 2023 EX-99.1 Exhibit 99.1 Press release Stockholm, Sweden, 10 Maj, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. Sobi to |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Cleopatra Acquisition Corp., a Delaware corporation and a wholly owned, indirect subsidiary of Parent (“Purchaser”), and each of the undersigned stoc |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Cleopatra Acquisition Corp., a Delaware corporation and a wholly owned, indirect subsidiary of Parent (“Purchaser”), and each of the undersigned stoc |
|
| May 10, 2023 |
SC14D9C 1 d436727dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other Jurisdictio |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 13, 2023 |
CTIC / CTI BioPharma Corp / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CTI BioPharma Corp. (Name of Issuer) Common Stock, par value $0.001per share (Title of Class of Securities) 12648L601 (CUSIP Number) April 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| March 24, 2023 |
CTIC / CTI BioPharma Corp / LYNCH TIMOTHY P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CTI BioPharma Corp. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 12648L601 (CUSIP Number) March 17, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28386 CTI BIOPHARMA |
|
| March 6, 2023 |
Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (“certificate |
|
| March 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) ( |
|
| March 6, 2023 |
Exhibit 99.1 CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results – Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentatio |
|
| February 13, 2023 |
CTIC / CTI BioPharma Corp / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* CTI BioPharma Corp. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 12648L601 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 9, 2023 |
CTIC / CTI BioPharma Corp / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 CTICSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) CTI BIOPHARMA CORP. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 12648L601 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriat |
|
| November 7, 2022 |
Exhibit 99.1 CTI BioPharma Reports Third Quarter 2022 Financial Results ? VONJO? (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter ? ? Increase in sales reflects strong growth in new patient starts ? ? Oral presentation of new data on pacritinib?s ACVR1 inhibition and anemia benefit in myelofibrosis patients at ASH 2022 ? ? Manage |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CO |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization |
|
| September 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organizati |
|
| September 28, 2022 |
September 2022 Corporate Deck Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading pr |
|
| August 23, 2022 |
August 23, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 16, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 16, 2022 Registration No. |
|
| August 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CTI BioPharma Corp. |
|
| August 17, 2022 |
Open Market Sale Agreement℠, dated August 16, 2022, between CTI BioPharma Corp. and Jefferies LLC. Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM August 16, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: CTI BioPharma Corp., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Com |
|
| August 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 8)1 CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) JAMES KRATKY BVF Partners L |
|
| August 8, 2022 |
Exhibit 99.1 CTI BioPharma Reports Second Quarter 2022 Financial Results ? VONJO? (pacritinib) net product revenue of $12.3 million in the second quarter ? ? Management to host conference call today at 4:30 p.m. ET ? SEATTLE, August 8, 2022 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022. ?CTI continues to make substantial headwa |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. ( |
|
| August 8, 2022 | ||
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| July 22, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 |
|
| June 17, 2022 |
SC 13D/A 1 cti-geo518625.htm GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. SCHEDULE 13D/A(#3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) Louis S. Citron, Esq |
|
| June 16, 2022 |
As filed with the Securities and Exchange Commission on June 16, 2022 As filed with the Securities and Exchange Commission on June 16, 2022 Registration No. |
|
| June 16, 2022 |
alculation of Filing Fee Tables Exhibit 107.1 FORM S-8 (Form Type) CTI BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per share Rule 457(a) ( |
|
| June 13, 2022 |
CTIC / CTI BioPharma Corp / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CTI BIOPHARMA CORP. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 12648L601 (CUSIP Number) JUNE 7, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| June 3, 2022 |
CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan. Exhibit 10.1 AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN CTI BIOPHARMA CORP. 1. PURPOSE OF PLAN The purpose of this CTI BioPharma Corp. 2017 Equity Incentive Plan (this ?Plan?) of CTI BioPharma Corp., a Delaware corporation (the ?Corporation?), is to promote the success of the Corporation by providing an additional means through the grant of awards to attract, motivate, retain and reward selec |
|
| June 3, 2022 |
CTI BioPharma Corp. Amended and Restated 2007 Employee Stock Purchase Plan Exhibit 10.2 AMENDED AND RESTATED 2007 EMPLOYEE STOCK PURCHASE PLAN CTI BIOPHARMA CORP. Effective as of September 27, 2007, amended and restated as of July 27, 2015, April 8, 2021 and April 18, 2022. 1. PURPOSE. The CTI BioPharma Corp. 2007 Employee Stock Purchase Plan (the ?Plan?) is intended to encourage ownership of stock by employees of CTI BioPharma Corp., a Washington corporation (the ?Compa |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) (C |
|
| May 12, 2022 |
Exhibit 99.1 CTI BioPharma Reports First Quarter 2022 Financial Results ? Strong U.S. commercial launch of VONJOTM (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia ? ? VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch, exceeding initial Company expectations ? ? VONJO inc |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) (C |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| March 31, 2022 |
Exhibit 4.4 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (?certificate |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28386 CTI BIOPHARMA |
|
| March 31, 2022 |
SECOND AMENDMENT TO LEASE DC ccvYl kte.v THIS SECONp?AMENDMENT TO LEASE (this "Amendment") is made as of the Lf!V' day of Nevfurber. 2021, by and between SELIG HOLDINGS COMPANY, LLC, a Delaware limited liability company ("Selig" or "Lessor"), and CTI BIOPHARMA CORP., a Delaware corporation ("CTI" or "Lessee"). WIT NE S S ET H: WHEREAS, Lessor and Cell Therapeutics, Inc. ("Original Tenant"), predec |
|
| March 31, 2022 |
Exhibit 99.1 CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results ? VONJOTM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway ? ? $60 Million Payment from DRI Healthcare Trust Triggered by FDA Approval under the Terms of the Previously Announced Debt and Royalty Transaction ? SEATT |
|
| March 4, 2022 |
Offer Letter, by and between CTI BioPharma Corp. and James K. Fong, dated as of March 1, 2022 Exhibit 10.1 February 28, 2022 Jim Fong (Delivered via email) Dear Jim: On behalf of CTI BIOPHARMA CORP. (CTI) Board of Directors, I am very pleased to promote you to the position of Senior Vice President and Chief Commercial Officer reporting to Bruce Seeley, Executive Vice President and Chief Operating Officer. The effective date for this promotion will be today. The Senior Vice President and Ch |
|
| March 4, 2022 |
EX-10.3 4 d291963dex103.htm EX-10.3 Exhibit 10.3 AMENDMENT TO SEVERANCE AGREEMENT THIS AMENDMENT (this “Amendment”) to the Severance Agreement dated January 6, 2015 (the “Agreement”) is made and entered into this 1st day of March, 2022 (the “Effective Date”), by and between CTI BioPharma Corp., a Delaware corporation (the “Company”), and James Fong (the “Employee”). RECITALS THE PARTIES ENTER THIS |
|
| March 4, 2022 |
Exhibit 10.2 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT (this ?Agreement?) is made and entered into this 6th day of January 2015 (the ?Effective Date?), by and between CTI BioPharma Corp., a Washington corporation (the ?Company?), and James Fong (the ?Employee?). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A. The Employee is curre |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 CTI BIOPHARMA CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 000-28386 91-1533912 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) ( |
|
| March 2, 2022 |
Exhibit 99.1 CTI BioPharma Announces FDA Accelerated Approval of VONJO? (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia ? VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients ? ? NDA Approved Under Priority Review ? ? Approval Triggers $60 Million Payment from DRI Healthcare Trust ? ? CTI to Host Co |
|
| February 14, 2022 |
CTIC / CTI BioPharma Corp / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* CTI BioPharma Corp. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 12648L601 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
CTIC / CTI BioPharma Corp / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 6, 2021 |
CUSIP No. 12648L601 SCHEDULE 13G Page 7 of 7 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this amendment to Schedule 13G, dated December 6, 2021 (the ?Schedule 13G?), with respect to the Common Stock of CTI BioPharma Corp. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as ame |
|
| December 6, 2021 |
CTIC / CTI BioPharma Corp / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2021 |
Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CO |
|
| November 12, 2021 |
Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 25, 2021 |
Exhibit 99.1 CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors ? Biopharma Commercial Leader Brings Significant Expertise Launching Novel Oncology Therapies ? SEATTLE, WA, August 24, 2021 - CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therap |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. ( |
|
| August 5, 2021 |
Exhibit 99.1 CTI BioPharma Reports Second Quarter 2021 Financial Results ? NDA for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Under Priority Review by FDA with PDUFA Target Action Date of November 30, 2021 ? ? Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United States in 2021 ? ? Management to Host Co |
|
| June 17, 2021 |
As filed with the Securities and Exchange Commission on June 17, 2021 As filed with the Securities and Exchange Commission on June 17, 2021 Registration No. |
|
| June 17, 2021 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CTI BIOPHARMA CORP. Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware (the ?DGCL?), CTI BIOPHARMA CORP., a corporation organized and existing under the provisions of the DGCL, DOES HEREBY CERTIFY: FIRST: That the name of the corporation is CTI BioPharma Corp. (the ?Corporation?), and that the Corporation wa |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) (C |
|
| June 7, 2021 |
CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan Exhibit 10.1 AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN CTI BIOPHARMA CORP. 1. PURPOSE OF PLAN The purpose of this CTI BioPharma Corp. 2017 Equity Incentive Plan (this ?Plan?) of CTI BioPharma Corp., a Delaware corporation (the ?Corporation?), is to promote the success of the Corporation by providing an additional means through the grant of awards to attract, motivate, retain and reward selec |
|
| June 7, 2021 |
CTI BioPharma Corp. Amended and Restated 2007 Employee Stock Purchase Plan Exhibit 10.2 AMENDED AND RESTATED 2007 EMPLOYEE STOCK PURCHASE PLAN CTI BIOPHARMA CORP. Effective as of September 27, 2007, amended and restated as of July 27, 2015 and April 8, 2021. 1.PURPOSE. The CTI BioPharma Corp. 2007 Employee Stock Purchase Plan (the ?Plan?) is intended to encourage ownership of stock by employees of CTI BioPharma Corp., a Washington corporation (the ?Company?), and certain |
|
| June 1, 2021 |
Exhibit 99.1 CTI BioPharma Reports First Quarter 2021 Financial Results ? NDA for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Accepted with Priority Review by FDA with PDUFA Target Action Date of November 30, 2021 ? ? Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United States in 2021 ? ? Management to |
|
| June 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) (C |
|
| May 6, 2021 |
CTI BioPharma Corp. Director Compensation Policy Exhibit 10.1 CTI BIOPHARMA CORP. DIRECTOR COMPENSATION POLICY Effective March 10, 2021 Directors of CTI BioPharma Corp., a Delaware corporation (the ?Company?), who are not employed by the Company or one of its subsidiaries (?non-employee directors?) shall be entitled to the compensation set forth below for their service as a member of the Board of Directors (the ?Board?) of the Company. Except as |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Sta |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 (March 31, 2021) CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation o |
|
| April 6, 2021 |
Certification of Designation of Preferences, Rights and Limitations of Series EX-3.1 3 d22360dex31.htm EX-3.1 Exhibit 3.1 CTI BIOPHARMA CORP. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CTI BIOPHARMA CORP., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL” |
|
| April 6, 2021 |
Underwriting Agreement by and among the Company and the Representatives, dated as of March 31, 2021 Exhibit 1.1 14,260,800 Shares of Common Stock 600 Shares of Series X1 Preferred Stock CTI BIOPHARMA CORP. UNDERWRITING AGREEMENT March 31, 2021 STIFEL, NICOLAUS & COMPANY, INCORPORATED JMP SECURITIES LLC As representative of the several Underwriters named in Schedule I hereto c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Ave, 12th Floor New York, NY 10019 c/o JMP Securities LLC 600 Mont |
|
| April 2, 2021 |
14,260,800 Shares of Common Stock 600 Shares of Series X1 Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251161 PROSPECTUS SUPPLEMENT (To prospectus dated December 15, 2020) 14,260,800 Shares of Common Stock 600 Shares of Series X1 Preferred Stock We are offering shares of our common stock, par value $0.001 per share, or, for certain investors, shares of our Series X1 convertible preferred stock, par value $0.001 per share, |
|
| March 31, 2021 |
SUBJECT TO COMPLETION, DATED March 31, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251161 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. The registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28386 CTI BIOPHARMA |
|
| March 17, 2021 |
EX-99.1 2 ex991earningsreleaseq42020.htm EX-99.1 Exhibit 99.1 CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results – Completion of Rolling NDA Submission for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Expected this Month – – Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United Stat |
|
| March 17, 2021 |
Exhibit 4.5 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, as amended (certificate of incorp |
|
| March 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| March 17, 2021 |
CTI BioPharma Corp. Stock Option Agreement (Inducement Form) Exhibit 10.29 CTI BIOPHARMA CORP. STOCK OPTION AGREEMENT (INDUCEMENT FORM) THIS STOCK OPTION AGREEMENT, including any country-specific appendices attached hereto, (collectively the ?Option Agreement?) is dated as of (the ?Grant Date?) by and between CTI BioPharma Corp., a Delaware corporation (the ?Corporation?), and (the ?Participant?). Capitalized terms used herein and not otherwise defined shal |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) James Kratky BVF Partners L |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CTI BioPharma Corp. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 12648L601 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization |
|
| January 15, 2021 |
Up to $50,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251161 PROSPECTUS SUPPLEMENT (To prospectus dated December 15, 2020) Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and |
|
| January 15, 2021 |
Open Market Sale Agreement℠, dated January 15, 2021, between CTI BioPharma Corp. and Jefferies LLC. EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM January 15, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: CTI BioPharma Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| December 11, 2020 |
December 11, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 7, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 4, 2020 Registration No. |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CO |
|
| November 10, 2020 |
Exhibit 10.1 CTI BIOPHARMA CORP. 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT, including any country-specific appendices attached hereto, (collectively the “Option Agreement”) is dated as of (the “Grant Date”) by and between CTI BioPharma Corp., a Delaware corporation (the “Corporation”), and (the “Participant”). Capitalized terms used herein and not otherwise defi |
|
| November 10, 2020 |
Exhibit 99.1 CTI BioPharma Reports Third Quarter 2020 Financial Results ? Rolling NDA Submission for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia Initiated in October ? ? Completion of Submission Expected in First Quarter 2021 ? ? Management to Host Conference Call Today at 4:30 PM ET ? SEATTLE, Nov. 10, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial re |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organizatio |
|
| October 2, 2020 |
CTIC / CTI BioPharma Corp. / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 29, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation) (Commission |
|
| September 29, 2020 |
EX-99.1 Exhibit 99.1 CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia – Company to Proceed with Rolling NDA Submission following Recent Pre-NDA Meeting with FDA – – Rolling NDA Expected to Commence in the Fourth Quarter of 2020 – – Completion of NDA Submission Expected in First Q |
|
| August 7, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF CTI BIOPHARMA CORP. CTI BioPharma Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is CTI BioPharma Corp. The date of filing of the Corporation’s original Certifi |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. ( |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| August 6, 2020 |
CTI BioPharma Reports Second Quarter 2020 Financial Results Exhibit 99.1 CTI BioPharma Reports Second Quarter 2020 Financial Results SEATTLE, Aug. 6, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020. “This past quarter we announced enrollment of the first patient in our PRE-VENT Phase 3 clinical trial of pacritinib in hospitalized patients with severe COVID-19, an impor |
|
| June 19, 2020 |
As filed with the Securities and Exchange Commission on June 19, 2020 Registration No. |
|
| June 19, 2020 |
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. Exhibit 23.2 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan of our report dated March 12, 2020, with respect to the consolidated financial statements of CTI BioPharma Corp. included in its Annual Rep |
|
| June 19, 2020 |
Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1). Exhibit 5.1 [Letterhead of Gibson, Dunn & Crutcher LLP] June 18, 2020 CTI BioPharma Corp. 3101 Western Avenue, Suite 800 Seattle, Washington 98121 Re: CTI BioPharma Corp. Registration Statement on Form S-8 Ladies and Gentleman: We have examined the Registration Statement on Form S-8 (the “Registration Statement”) of CTI BioPharma Corp., a Delaware corporation (the “Company”), to be filed with the |
|
| June 19, 2020 |
Exhibit 4.4 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF CTI BIOPHARMA CORP. CTI BioPharma Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the Corporation is CTI BioPharma Corp. The date of filing of the Corporation’s original Certifi |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) (C |
|
| June 10, 2020 |
CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan. Exhibit 10.1 AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN CTI BIOPHARMA CORP. 1. PURPOSE OF PLAN The purpose of this CTI BioPharma Corp. 2017 Equity Incentive Plan (this “Plan”) of CTI BioPharma Corp., a Delaware corporation (the “Corporation”), is to promote the success of the Corporation by providing an additional means through the grant of awards to attract, motivate, retain and reward selec |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28386 CTI BIOPHARMA CORP. |
|
| May 7, 2020 |
CTI BioPharma Reports First Quarter 2020 Financial Results Exhibit 99.1 CTI BioPharma Reports First Quarter 2020 Financial Results SEATTLE, May 7, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. “With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a potential treatment for severely thrombocytopenic myelofibro |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-kearningsreleaseq12020.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdicti |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta |
|
| April 22, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| April 13, 2020 |
CTI / CTI BIOPHARMA CORP PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| April 13, 2020 |
Amended and Restated Bylaws of CTI BioPharma Corp., a Delaware corporation. AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I REGISTERED OFFICE 1.1 Delaware Office. The Corporation shall have and maintain a registered office in the State of Delaware as required by law. The name and address of its registered agent in the State of Delaware is set forth in the Certificate of Incorporation of the Corporation (the Certificate of Incorporation) |
|
| March 13, 2020 |
Exhibit 10.46 CTI BIOPHARMA CORP. DIRECTOR COMPENSATION POLICY Effective March 13, 2019 Directors of CTI BioPharma Corp., a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“non-employee directors”) shall be entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. Except a |
|
| March 13, 2020 |
CTI / CTI BIOPHARMA CORP 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28386 CTI BIOPHARMA |
|
| March 13, 2020 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of CTI BioPharma Corp. Material subsidiaries of CTI BioPharma Corp. include Aequus Biopharma, Inc., a Washington corporation. |
|
| March 13, 2020 |
Exhibit 4.6 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, as amended (certificate of incorp |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) |
|
| March 12, 2020 |
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results Exhibit 99.1 CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results SEATTLE, Mar. 12, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019. “In the latter half of 2019 and beginning of 2020, we further advanced our pacritinib development program, including presenting data at the American Socie |
|
| March 12, 2020 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 |
|
| March 10, 2020 |
CUSIP No. 12648L 601 SCHEDULE 13G Page 7 of 7 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this amendment to Schedule 13G, dated March 10, 2020 (the “Schedule 13G”), with respect to the Common Stock of CTI BioPharma Corp. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amen |
|
| March 10, 2020 |
CTI / CTI BIOPHARMA CORP / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss168660sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) CTI BioPharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 12648L 601 (CUSIP Number) March 6, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| March 9, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 CTI BIOPHARMA CORP. (Exact name of registrant as specified in its charter) Delaware 000-28386 91-1533912 (State or other jurisdiction of incorporation or organization) ( |
|
| March 9, 2020 |
Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1) Exhibit 5.1 March 6, 2020 CTI BioPharma Corp. 3101 Western Avenue, Suite 800 Seattle, Washington 98191 Re: CTI BioPharma Corp. Registration Statement on Form S‑3 (File No. 333-221382) Ladies and Gentlemen: We have examined the Registration Statement on Form S-3, File No. 333-221382, as amended (the “Registration Statement”), of CTI BioPharma Corp., a Delaware corporation (the “Company”), filed wit |
|
| March 9, 2020 |
CTI BioPharma Corp. Press Release, dated March 6, 2020 Exhibit 99.1 CTI BioPharma Announces Closing of Rights Offering SEATTLE, March 6, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995 shares of its common stock (the “Common Stock”) and an aggregate of 4,429.2423 shares of its series X conv |
|
| March 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 CTI BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 12648L601 (CUSIP Number) JAMES KRATKY BVF PARTNERS L |
|
| February 14, 2020 |
CTI BioPharma Announces Commencement of Rights Offering EX-99.8 Exhibit 99.8 CTI BioPharma Announces Commencement of Rights Offering SEATTLE, February 14, 2020 - CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the “Rights Offering”). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on February 13, 2020, of CTI BioPharm |
